| abstract |
A drug, specifically, a novel arylamidrazone derivative having an antagonistic effect on an S1P3 receptor; and a medicine containing the drug as an active ingredient. The drug is an arylamidrazone derivative represented by the following general formula (1): (1) [wherein R1 represents optionally substituted C2-8 alkyl, optionally substituted phenyl, an optionally substituted aromatic heterocyclic group, optionally substituted C2-8 alkoxy, or -NR4R5 (wherein R4 and R5 are the same or different and each represents hydrogen or optionally substituted lower alkyl, provided that R4 and R5 may form an optionally substituted nitrogenous heterocycle in cooperation with the adjacent nitrogen atom); R2 and R3 are the same or different and each represents hydrogen, halogeno, lower haloalkyl, lower alkyl, lower alkynyl, lower alkoxy, cyano, lower alkanoyl, or lower alkylsulfonyl; A represents a benzene ring or heterocycle; D represents a single bond or methylene; and m is an integer of 1-3 and n is an integer of 1-5 (provided that the following cases are excluded: R1 is ethoxy, R2 is 2,4-dichloro, R3 is hydrogen, A is a benzene ring, and D is methylene; and R1 is ethoxy, R2 is 2,4-dichloro, R3 is hydrogen, 2-methyl, 4-methyl, 4-methoxy, or 4-ethoxy, A is a benzene ring, and D is a single bond).] or a pharmaceutically acceptable salt of the derivative. |